Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Novartis AG (NVS)
Price$137.52Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.53B | $50.32B | $45.44B | $42.21B | $42.78B | $48.66B | $47.50B | $44.83B | $42.38B | $48.52B |
| Gross profit | $42.98B | $38.90B | $34.19B | $31.88B | $32.24B | $34.78B | $34.25B | $31.59B | $29.77B | $31.92B |
| Gross margin | 78.81% | 77.30% | 75.24% | 75.53% | 75.36% | 71.47% | 72.11% | 70.46% | 70.25% | 65.78% |
| Research & development | $11.20B | $10.02B | $11.37B | $9.17B | $8.64B | $8.98B | $9.40B | $8.49B | $8.39B | $9.04B |
| Operating expenses | $25.33B | $24.35B | $24.42B | $23.93B | $22.18B | $24.63B | $25.17B | $23.19B | $21.07B | $23.65B |
| Operating income | $17.64B | $14.54B | $9.77B | $7.95B | $10.06B | $10.15B | $9.09B | $8.40B | $8.70B | $8.27B |
| Operating margin | 32.36% | 28.90% | 21.50% | 18.83% | 23.51% | 20.86% | 19.13% | 18.74% | 20.53% | 17.04% |
| EBITDA | $18.59B | $15.43B | $18.25B | $9.11B | $11.26B | — | — | — | — | — |
| EBITDA margin | 34.10% | 30.66% | 40.17% | 21.58% | 26.33% | — | — | — | — | — |
| Net income | $13.97B | $11.94B | $14.85B | $6.96B | $24.02B | $8.07B | $11.74B | $12.61B | $7.70B | $6.70B |
| Net profit margin | 25.61% | 23.73% | 32.69% | 16.48% | 56.14% | 16.59% | 24.71% | 28.14% | 18.18% | 13.81% |
| Basic EPSper basic share | $7.21 | $5.92 | $7.15 | $3.19 | $10.71 | $3.55 | $5.12 | $5.44 | $3.28 | $2.82 |
| Diluted EPSper diluted share | $7.15 | $5.87 | $7.10 | $3.17 | $10.63 | $3.52 | $5.06 | $5.38 | $3.25 | $2.80 |
Insider buys & sells
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...